WASHINGTON, DC (March 18, 2019) – Karin Hessler joins the Association for Accessible Medicines as Assistant General Counsel, effective today.
“Through her extensive legal representation of manufacturers of generic and biosimilar medicines, Karin will bring valuable insights into the intellectual property barriers that our companies face in trying to deliver safe, more affordable treatment options to patients,” said Jeff Francer, AAM’s Senior Vice President and General Counsel.
Hessler will focus primarily on Hatch-Waxman, biosimilar and pharmaceutical patent issues.
Before joining AAM in March 2019, Hessler was a partner at Wiley Rein LLP, where she represented clients on intellectual property matters, with a special focus on patent litigation in the biotechnology and medical device industries. She has played a lead role in all phases of numerous Hatch-Waxman litigations, including expert discovery, fact discovery, claim construction, trials, regulatory analysis and settlement negotiations.
Hessler received her J.D. from NYU School of Law, an M.A. in biochemistry from Duke and her B.S. in biochemistry from Lafayette College.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.